A detailed history of Oppenheimer Asset Management Inc. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 13,396 shares of SWTX stock, worth $501,546. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,396
Previous 13,568 1.27%
Holding current value
$501,546
Previous $511,000 16.05%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$32.04 - $42.76 $5,510 - $7,354
-172 Reduced 1.27%
13,396 $429,000
Q2 2024

Aug 08, 2024

BUY
$36.06 - $47.62 $140,345 - $185,337
3,892 Added 40.22%
13,568 $511,000
Q1 2024

May 06, 2024

SELL
$36.5 - $52.5 $25,477 - $36,645
-698 Reduced 6.73%
9,676 $476,000
Q4 2023

Feb 13, 2024

SELL
$18.94 - $37.24 $23,996 - $47,183
-1,267 Reduced 10.88%
10,374 $378,000
Q3 2023

Nov 07, 2023

SELL
$23.12 - $31.38 $1,086 - $1,474
-47 Reduced 0.4%
11,641 $269,000
Q2 2023

Aug 02, 2023

BUY
$23.15 - $32.71 $270,577 - $382,314
11,688 New
11,688 $306,000
Q3 2022

Nov 14, 2022

SELL
$24.1 - $39.66 $8,965 - $14,753
-372 Reduced 4.28%
8,310 $237,000
Q2 2022

Aug 08, 2022

SELL
$18.36 - $60.07 $4,131 - $13,515
-225 Reduced 2.53%
8,682 $214,000
Q1 2022

May 12, 2022

BUY
$48.97 - $65.46 $32,320 - $43,203
660 Added 8.0%
8,907 $503,000
Q4 2021

Feb 02, 2022

BUY
$53.3 - $75.84 $175,996 - $250,423
3,302 Added 66.77%
8,247 $511,000
Q3 2021

Nov 12, 2021

BUY
$62.66 - $88.26 $309,853 - $436,445
4,945 New
4,945 $314,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.34B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.